Inclusion Criteria:  Meet the diagnosis of AMI, prepare for PCI reperfusion therapy; Between the ages of 18-75; Volunteer to participate in this study and have signed an informed consent form; Have a correct understanding of the significance of drug research, and have a good compliance with the observation and evaluation.  Exclusion Criteria:  Not suitable for coronary intervention; With unstable hemodynamics; Platelet count<100×109; Suspected aortic dissection or acute pulmonary embolism; With mechanical complications; With uncontrolled acute left heart failure and pulmonary edema; With known bleeding history, active bleeding, bleeding constitution, or severe hemostatic and coagulation dysfunction; Meantain anticoagulants (such as warfarin or new anticoagulants); Severe liver and kidney insufficiency (Child-Pugh B and above, Cr>177μmol/L (2mg/dl) or eGFR<45ml/min/1.73m2); CTO, stent stenosis, or severe left main disease; History of coronary artery bypass graft surgery; Other pathophysiological conditions whose expected survival period is less than 1 year; Allergic history to Suxiao Jiuxin Pills; Pregnant or lactating women; Participating in other clinical studies; With other diseases that are not suitable for participating in clinical research.